Journal of Neuro-Oncology

, 90:341

Low-grade gliomas in older patients: a retrospective analysis of prognostic factors

  • Nader Pouratian
  • Melike Mut
  • Jay Jagannathan
  • M. Beatriz Lopes
  • Mark E. Shaffrey
  • David Schiff
Clinical Study - Patient Study

DOI: 10.1007/s11060-008-9669-3

Cite this article as:
Pouratian, N., Mut, M., Jagannathan, J. et al. J Neurooncol (2008) 90: 341. doi:10.1007/s11060-008-9669-3

Abstract

Low-grade gliomas (LGG) are increasingly being diagnosed in older patients (≥60 years). The rising incidence is incompletely understood but demands an analysis of the natural history and prognostic factors to determine if there are differences compared to younger populations. We retrospectively review a consecutive series of 20 older patients who presented between 1991 and 2004 with LGG to characterize the presentation, management, outcomes, and prognostic factors in older patients with LGG. Median follow-up was 27.3 months. Thirty-five percent of patients harboured oligodendrogliomas. Patients presented in equal numbers with seizure, focal neurological deficit, and mental status change. Median overall survival (OS) was 27.3 months. Patients who survive beyond 2 years experience prolonged periods of progression-free survival. Younger age, seizure presentation, and radiation treatment were prognostic of OS on multivariate analysis. Similarities with previous reports of LGG suggest that age should not affect the management of LGG patients. Prospective studies of older patients with LGG are needed to further characterize the optimum management of these patients.

Keywords

Low-grade gliomaGliomaElderlyPrognosisRisk factors

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Nader Pouratian
    • 1
  • Melike Mut
    • 1
  • Jay Jagannathan
    • 1
  • M. Beatriz Lopes
    • 2
  • Mark E. Shaffrey
    • 1
  • David Schiff
    • 1
    • 3
    • 4
  1. 1.Department of Neurological SurgeryUniversity of VirginiaCharlottesvilleUSA
  2. 2.Department of Pathology, Division of NeuropathologyUniversity of VirginiaCharlottesvilleUSA
  3. 3.Department of NeurologyUniversity of VirginiaCharlottesvilleUSA
  4. 4.Department of Medicine (Hematology/Oncology)University of VirginiaCharlottesvilleUSA